Concizumab
| Clinical data | |
|---|---|
| Trade names | Alhemo |
| Routes of administration | Subcutaneous |
| Drug class | Antihemorrhagic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C6462H10004N1712O2046S46 |
| Molar mass | 145887.81 g·mol−1 |
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia B.[1] It is an anti-tissue factor pathway inhibitor.[1]
Concizumab was approved for medical use in Canada in March 2023.[3][4]
Medical uses
Concizumab is indicated for the treatment of people with hemophilia B who have factor IX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.[1][2]
Society and culture
Names
Concizumab is the international nonproprietary name.[5]
References
- 1 2 3 4 "Archived copy" (PDF). Archived (PDF) from the original on 17 April 2023. Retrieved 9 June 2023.
{{cite web}}: CS1 maint: archived copy as title (link) - 1 2 "Summary Basis of Decision for Alhemo". Health Canada. 31 May 2023. Retrieved 9 June 2023.
- 1 2 "Concizumab Product information". Health Canada. 10 March 2023. Archived from the original on 24 March 2023. Retrieved 9 June 2023.
- ↑ "Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors" (Press release). Novo Nordisk Canada. 17 April 2023. Retrieved 9 June 2023 – via Newswire.
- ↑ World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.